The Latest Breaking News from AstraZeneca

‘A lot of Covid-19 vaccine wastage has been driven by the deeply unequal global response to this pandemic,’ says global health campaigner

COVID vaccines have been contentious ever since they were developed in response to the coronavirus pandemic, though the evidence is that they are safe and effective. One of the concerns has been whether the vaccines were safe for pregnant women. A recent review looked at the evidence available from North…

Oxford AstraZeneca vaccine fell out of favour amid concerns about rare but potentially fatal blood clots

Reuters

Here's a roundup of top developments in the biotech space over the last 24 hours:

Oxford Biomedica plc (OTC:OXBDF) signed a new three-year agreement to potentially make AstraZeneca Plc's (NASDAQ:AZN) COVID-19 vaccine beyond 2022. The new agreement represents an expansion of the original master supply and development agreement announced between the two companies in September 2020. The manufacture of COVID-19 vaccines at Oxford Biomedica's Oxbox facility, as part of the…

As Australia approaches the grim milestone of 10,000 Covid deaths, we look at the people behind the numbers

The family of Katie Lees, who died after receiving a COVID-19 vaccine, say an arts fellowship in her name "lifts" them from being stuck in horror and grief, as they wait for clarity on an inquiry into the vaccine rollout.

Someone with a lot of money to spend has taken a bearish stance on AstraZeneca (NASDAQ:AZN). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.